Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24630405 | 0.74 | RAB9A (0.36) | MEN1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL23815751 | 0.70 | GFER (0.36) | RORCLMNAALDH1A1GAA | |
| SCHEMBL23815725 | 0.68 | SHMT2 (0.39) | MEN1CYP1A2KMT2ASMN1; SMN2RORC | |
| SCHEMBL23682669 | 0.65 | GFER (0.36) | CYP1A2KMT2ASMN1; SMN2RORCLMNA | |
| SCHEMBL2952498 | 0.62 | CA1 (0.42) | — | |
| SCHEMBL2880579 | 0.62 | COPS5 (0.35) | RORC | |
| SCHEMBL2753265 | 0.62 | LMNA (0.35) | SMN1; SMN2TP53LMNAGAA | |
| SCHEMBL23815752 | 0.62 | GAA (0.44) | MEN1CYP1A2KMT2ASMN1; SMN2TP53 | |
| SCHEMBL1845956 | 0.61 | PIK3CA (0.45) | MEN1CYP1A2KMT2ASMN1; SMN2RORC | |
| SCHEMBL8554826 | 0.58 | ALDH1A1 (0.50) | MEN1CYP1A2KMT2ASMN1; SMN2PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117760-A1 | Dna minor groove binding compounds | UNIVERSITY OF STRATHCLYDE (GB) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117760-A1 | Dna minor groove binding compounds | PCNA, POLL, POLM | MEN1 2072/4885CYP1A2 4808/4885KMT2A 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.